Ukraine Utilizes Cryptocurrency Donations for Military Equipment Amidst Invasion\n\nUkraine has found a unique solution to its urgent need for military equipment amidst the ongoing invasion by Russia. The country has turned to cryptocurrency donations, with its deputy digital minister claiming that 60% of suppliers were able to accept crypto in exchange for combat essentials such as helmets and bulletproof vests.\n\nOne year ago, Russian president Vladimir Putin began the invasion of Ukraine. In response, the Ukrainian government took to Twitter to request cryptocurrency donations, including bitcoin, ethereum, and the USDT stablecoin. These donations have been transparently recorded on the blockchain, with over 100,000 people contributing, including some from Russia.\n\nIn an interview with Yahoo Finance UK’s The Crypto Mile, Ukrainian deputy digital minister Alex Bornyakov explained that the country needed immediate help and turned to crypto because using the traditional financial system would have taken days. He also noted that around 60% of suppliers were able to accept crypto, which was unexpected.\n\nThe success of this initiative can be seen through the Crypto Fund Aid For Ukraine, which has raised $54 million and has been supported by the Ministry of Digital Transformation of Ukraine. This has allowed Ukraine to purchase military equipment, including medical kits, rifle scopes, and thermal imagers.\n\nThe use of cryptocurrency donations has proven to be faster and more efficient than the traditional financial system, with Ukraine’s vice prime minister Mykhailo Fedorov stating that it has been crucial in supplying their defenders with necessary equipment. This solution would not have been possible without the support of the crypto community.

'FDA Approves Arcutis Biotherapeutics' Drug for Seborrheic Dermatitis\n\nThe U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics' drug for treating seborrheic dermatitis in individuals nine years of age and older. This marks the first topical drug with a new mechanism of action to be approved for this condition in over two decades.\n\nSeborrheic dermatitis is a common, chronic, and recurrent inflammatory skin disease that affects more than 10 million people in the United States. It causes red patches covered with large, greasy, flaking yellow-gray scales, and persistent itch. The condition can be especially burdensome for those with hair loss, as it often occurs in areas of the body with oil-producing glands.\n\nArcutis Biotherapeutics' drug, called ZORYVE foam, is a once-daily, steroid-free topical treatment that can be used on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use. In clinical trials, nearly 80% of individuals achieved the primary efficacy endpoint of IGA Success, and over 50% reached complete clearance at Week 8.\n\n"We know from dermatology clinicians and those living with seborrheic dermatitis that there has been a real struggle with disease clearance and treatment adherence due to lack of efficacy, difficulty treating certain body areas, inconvenient treatment regimens, and concerns about safety with long-term use," said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. "ZORYVE foam is a once-daily, steroid-free topical treatment that can be used anywhere on the body, including hair-bearing areas, with no limitation on duration of use."\n\nThis approval is a significant milestone for Arcutis Biotherapeutics and offers a new treatment option for the millions of adults and adolescents living with seborrheic dermatitis. The company expects the commercial product to be available by the end of January.'